NCT07039994

Brief Summary

Palliative care has long been associated primarily with end-of-life support. However, its scope is much broader. As highlighted in the Hastings Center Report, the purposes of medicine include not only curing disease but also preventing illness, relieving suffering, caring for patients, avoiding preventable deaths, and ensuring a peaceful death when unavoidable. Palliative care plays a vital role in achieving all of these goals. In addition to pain and symptom management, it addresses the prevention of complicated grief, the emergence of severe symptoms (e.g., constipation, delirium), the inappropriate use of end-of-life treatments, and offers specialized care for incurable diseases. This model of care follows a multidimensional and multidisciplinary approach, focusing on the person beyond the illness and addressing emotional, social, spiritual, and practical needs. Recent studies have shown that early integration of palliative care within routine oncology improves symptom control, emotional well-being, and coping with the illness. Furthermore, it enhances quality of life for both patients and their families, reduces healthcare resource usage, and does not increase overall health expenditure. Such early integration also facilitates discussions about end-of-life issues, promotes advance care planning, and supports improved home-based palliative care. Additionally, it has been associated with fewer aggressive treatments and a positive impact on patient survival. Systematic symptom assessment leads to earlier and more effective management. In this context, information and communication technologies (ICTs) have shown promise in enabling remote monitoring and care delivery. These tools can enhance quality of life, improve treatment adherence, reduce emergency visits, and positively influence survival. However, existing studies have limitations, such as small sample sizes and lack of evaluator blinding. The COVID-19 pandemic emphasized the need for physical distancing and accelerated the development of remote healthcare systems. Some specialized cancer centers, like the Institut Català d'Oncologia, have implemented functional multidisciplinary units for each cancer type. These units consist of various specialists (medical oncologists, radiation oncologists, surgeons, radiologists, pathologists, advanced practice nurses, palliative care professionals, etc.) who collaboratively decide the best course of treatment. A key role within these units is the reference nurse, assigned to each patient, who acts as a main point of contact, available for in-person or phone consultations. One major improvement in recent years has been the integration of palliative care clinics within oncology departments. Best practices now emphasize early palliative intervention based on patient complexity and needs. While no universal definition exists, most studies define "early palliative care" as involvement by a palliative team within the first three months following a diagnosis of advanced cancer. This approach is supported by multiple scientific societies. Nevertheless, challenges such as limited resources, accessibility barriers, and increasing in-person demand near the end of life remain significant obstacles. Among advanced cancers, lung cancer stands out due to its high prevalence and poor prognosis. It is characterized by frequent and unpredictable symptoms, requiring flexible and responsive follow-up. Adapting care to patients' changing needs could improve quality of life, optimize resources, and reduce the frequency of in-person visits. This study proposes the integration of early palliative care with an e-Health ecosystem, reflecting the global push to bring care into the homes of vulnerable patients using modern technology. Evidence for the impact of ICTs in palliative care remains limited, and existing studies are generally of low quality. To date, only one registered trial (NCT03375489) has explored e-Health in early palliative care. Unlike that study, this research offers a scalable model tailored to patient complexity, alongside a comprehensive cost-utility evaluation (e.g., fewer in-person visits, emergency care use, and patient transfers to care centers). This is the first international clinical trial of its kind in palliative care. It is a multicenter, randomized, controlled trial with blinded third-party evaluation. The hypothesis is that an e-Health ecosystem with ICT tools will improve access, early detection, monitoring, and remote palliative intervention for lung cancer patients.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable nonsmall-cell-lung-cancer

Timeline
27mo left

Started Dec 2024

Typical duration for not_applicable nonsmall-cell-lung-cancer

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress38%
Dec 2024Jul 2028

Study Start

First participant enrolled

December 24, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 2, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

June 26, 2025

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 24, 2028

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 24, 2028

Last Updated

June 26, 2025

Status Verified

June 1, 2025

Enrollment Period

3.2 years

First QC Date

June 2, 2025

Last Update Submit

June 18, 2025

Conditions

Keywords

Palliative Caree-HealthTelemedicineEarly Treatment

Outcome Measures

Primary Outcomes (1)

  • FACT-L

    Functional Assessment of Cancer Therapy-Lung Minimum and maximum values: 0-136 worst to best quality of life

    Baseline, 3, 6, 9 and 12 months

Secondary Outcomes (19)

  • ESAS-r

    Baseline, 3, 6, 9 and 12 months

  • HADS

    Baseline, 3, 6, 9 and 12 months

  • EQ-5D-3L

    Baseline, 3, 6, 9 and 12 months

  • ARMS

    Baseline, 3, 6 ,9 and 12 months

  • CTCAE

    Baseline, 3, 6, 9 and 12 months

  • +14 more secondary outcomes

Study Arms (2)

E-health follow-up

EXPERIMENTAL
Other: E-health intervention

Standard follow-up

ACTIVE COMPARATOR
Other: Standard intervention

Interventions

Routine intervention in the service: * Good control: In-person visit every 4 weeks. * Poor control: Nurse calls at 1 week to assess and decide on treatment changes, visits, or referral. In-person visit by need or after 1 month.

Standard follow-up

Combined system using ICT and in-person care. It includes spontaneous use (symptom tracking, messages, reminders via app) and scheduled use: * Good symptom control: Basic Telematic Evaluation (BTE) at 1 month. If stable, videoconference at 2 months, BTE at 3 months, and in-person visit at 4 months. * Poor symptom control: BTE at 1 week. If warning signs appear, a nurse evaluates by phone and may adjust treatment, schedule a visit (in-person or video), or refer to emergency care. In-person visit by need or after 1 month.

E-health follow-up

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with advanced NSCLC (stage III or IV) with criteria for early palliative intervention\*, seen in the initial palliative care consultation.
  • Patients or primary caregivers with internet proficiency and access to computer and telephone equipment.
  • Patients with ECOG performance status 0-3
  • For the purposes of this study, patients with the following conditions will be considered candidates for early palliative care: a tumor diagnosis ≤3 months prior to diagnosis and one or more of the following criteria: average pain poorly controlled with opioids (VAS score ≥4); dyspnea on minor exertion; patients \<60 years of age; emotional distress (HADS ≥10); family fragility; functional limitation (Barthel \<60); history or use of drugs; and the presence of ethical or existential dilemmas (Llorens et al., 2017; Tuca et al., 2019).

You may not qualify if:

  • Patients who do not meet criteria for early palliative intervention.
  • Patients with severe cognitive impairment or psychiatric impairment that prevents proper evaluation.
  • Patients who do not speak or understand Catalan or Spanish adequately.
  • Patients who, at the first visit, are in a serious clinical condition that prevents proper evaluation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Catalan Institute of Oncology

Badalona, Barcelona, 08916, Spain

NOT YET RECRUITING

Catalan Institute of Oncology

L'Hospitalet de Llobregat, Barcelona, 08908, Spain

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Jesús González Barboteo, MD, PhD

    Catalan Institute of Oncology (ICO)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jesús González Barboteo, MD, PhD

CONTACT

Miguel Mateu Sanz, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Experimental group - e-Health follow-up, a combined system using ICT and in-person care. It includes spontaneous use (symptom tracking, messages, reminders via app) and scheduled use: * Good symptom control: Basic Telematic Evaluation (BTE) at 1 month. If stable, videoconference at 2 months, BTE at 3 months, and in-person visit at 4 months. * Poor symptom control: BTE at 1 week. If warning signs appear, a nurse evaluates by phone and may adjust treatment, schedule a visit (in-person or video), or refer to emergency care. In-person visit by need or after 1 month. Control group - Standard follow-up: * Good control: In-person visit every 4 weeks. * Poor control: Nurse calls at 1 week to assess and decide on treatment changes, visits, or referral. In-person visit by need or after 1 month.
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

June 2, 2025

First Posted

June 26, 2025

Study Start

December 24, 2024

Primary Completion (Estimated)

March 24, 2028

Study Completion (Estimated)

July 24, 2028

Last Updated

June 26, 2025

Record last verified: 2025-06

Locations